HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase inhibitors, or ‘statins’, have revolutionized the management of patients with atherosclerotic vascular disease. Following 2 large acute coronary syndrome trials, additional clinical benefit outside their effect of low-density lipoprotein (LDL) lowering was proposed. This concept was introduced following the observation of cardiovascular event rate reduction, only weeks after initiation of treatment and supposedly before the effect of LDL lowering could have influenced atheroma volume burden. Furthermore, there has been a substantial compilation of experimental data demonstrating beneficial effects of statins on inflammation, thrombosis, platelet aggregation, immunomodulation and endothelial function. These are hypothesized to occur via the interruption of the mevalonate pathway. However, the absolute benefit of these non-lipid-lowering effects, often referred to as ‘pleiotropic effects’, has been challenged by meta-analysis data. Anti-inflammatory actions have also been proposed to occur by the process of LDL lowering alone rather than due to a unique property of statins. Furthermore, some experimental data reports have shown evidence of pleiotropic effects in non-statin lipid-modifying agents. In this review article, we consolidate what is known so far and critically analyse the literature in order to highlight the outstanding issues.

Keywords:
Pleiotropic effects, Statins, Low-density lipoprotein lowering, Ezetimibe, Niacin, Fibrates
1.
Yachnin S: Mevalonic acid as an initiator of cell growth. Studies using human lymphocytes and inhibitors of endogenous mevalonate biosynthesis. Oncodev Biol Med 1982;3:111–123.
2.
Yachnin S, Richman DP: Mevalonic acid in conjunction with help from neutrophils induces DNA synthesis and cell cycling in human peripheral blood lymphocytes. Cell Immunol 1982;72:248–262.
3.
Cutts JL, Scallen TJ, Watson J, Bankhurst AD: Role of mevalonic acid in the regulation of natural killer cell cytotoxicity. J Cell Physiol 1989;139:550–557.
4.
Corsini A, Mazzotti M, Raiteri M, Soma MR, Gabbiani G, Fumagalli R, Paoletti R: Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase. Atherosclerosis 1993;101:117–125.
5.
Bernini F, Didoni G, Bonfadini G, Bellosta S, Fumagalli R: Requirement for mevalonate in acetylated LDL induction of cholesterol esterification in macrophages. Atherosclerosis 1993;104:19–26.
6.
Takemoto M, Sun J, Hiroki J, Shimokawa H, Liao JK: Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation 2002;106:57–62.
7.
Laufs U, Gertz K, Huang P, Nickenig G, Bohm M, Dirnagl U, Endres M: Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke 2000;31:2442–2449.
8.
Weitz-Schmidt G, Welzenbach K, Brinkmann V, Kamata T, Kallen J, Bruns C, Cottens S, Takada Y, Hommel U: Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001;7:687–692.
9.
Kurakata S, Kada M, Shimada Y, Komai T, Nomoto K: Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro. Immunopharmacology 1996;34:51–61.
10.
Kwak B, Mulhaupt F, Myit S, Mach F: Statins as a newly recognized type of immunomodulator. Nat Med 2000;6:1399–1402.
11.
Romano M, Diomede L, Sironi M, Massimiliano L, Sottocorno M, Polentarutti N, Guglielmotti A, Albani D, Bruno A, Fruscella P, Salmona M, Vecchi A, Pinza M, Mantovani A: Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab Invest 2000;80:1095–1100.
12.
Ray KK, Cannon CP, McCabe CH, Cairns R, Tonkin AM, Sacks FM, Jackson G, Braunwald E: Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2005;46:1405–1410.
13.
Kinlay S, Schwartz GG, Olsson AG, Rifai N, Leslie SJ, Sasiela WJ, Szarek M, Libby P, Ganz P: High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 2003;108:1560–1566.
14.
Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, Hutchinson WL, Pepys MB: C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999;99:237–242.
15.
Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001;285:1711–1718.
16.
Albert MA, Danielson E, Rifai N, Ridker PM: Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001;286:64–70.
17.
Puccetti L, Pasqui AL, Pastorelli M, Bova G, Cercignani M, Palazzuoli A, Angori P, Auteri A, Bruni F: Time-dependent effect of statins on platelet function in hypercholesterolaemia. Eur J Clin Invest 2002;32:901–908.
18.
Horvath B, Marton Z, Alexy T, Kesmarky G, Toth K, Szapary L: Short-term effects of atorvastatin on haemorheologic parameters, platelet aggregation and endothelium dysfunction in patients with hypercholesterolaemia. Eur Heart J 2004;25:96.
19.
Gaddam V, Li DY, Mehta JL: Anti-thrombotic effects of atorvastatin – an effect unrelated to lipid lowering. J Cardiovasc Pharmacol Ther 2002;7:247–253.
20.
Undas A, Celinska-Lowenhoff M, Domagala TB, Iwaniec T, Dropinski J, Lowenhoff T, Szczeklik A: Early antithrombotic and anti-inflammatory effects of simvastatin versus fenofibrate in patients with hypercholesterolemia. Thromb Haemost 2005;94:193–199.
21.
Kjekshus J, Apetrei E, Barrios V, Bohm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, Janosi A, Kamensky G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J: Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357:2248–2261.
22.
Yamada T, Node K, Mine T, Morita T, Kioka H, Tsukamoto Y, Tamaki S, Masuda M, Okuda K, Fukunami M: Long-term effect of atorvastatin on neurohumoral activation and cardiac function in patients with chronic heart failure: a prospective randomized controlled study. Am Heart J 2007;153:1055.e1–e8.
23.
Dickinson MG, Ip JH, Olshansky B, Hellkamp AS, Anderson J, Poole JE, Mark DB, Lee KL, Bardy GH: Statin use was associated with reduced mortality in both ischemic and nonischemic cardiomyopathy and in patients with implantable defibrillators: mortality data and mechanistic insights from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Am Heart J 2007;153:573–578.
24.
Khush KK, Waters DD, Bittner V, Deedwania PC, Kastelein JJ, Lewis SJ, Wenger NK: Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study. Circulation 2007;115:576–583.
25.
Tavazzi L, Tognoni G, Franzosi MG, Latini R, Maggioni AP, Marchioli R, Nicolosi GL, Porcu M: Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur J Heart Fail 2004;6:635–641.
26.
Bulut D, Hanefeld C, Bulut-Streich N, Graf C, Mugge A, Spiecker M: Endothelial function in the forearm circulation of patients with the metabolic syndrome – effect of different lipid-lowering regimens. Cardiology 2005;104:176–180.
27.
Dagli N, Yavuzkir M, Karaca I: The effects of high dose pravastatin and low dose pravastatin and ezetimibe combination therapy on lipid, glucose metabolism and inflammation. Inflammation 2007;30:230–235.
28.
Goldberg RB, Guyton JR, Mazzone T, Weinstock RS, Polis A, Edwards P, Tomassini JE, Tershakovec AM: Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study. Mayo Clin Proc 2006;81:1579–1588.
29.
Abud-Mendoza C, de la Fuente H, Cuevas-Orta E, Baranda L, Cruz-Rizo J, Gonzalez-Amaro R: Therapy with statins in patients with refractory rheumatic diseases: a preliminary study. Lupus 2003;12:607–611.
30.
Maki-Petaja KM, Booth AD, Hall FC, Wallace SM, Brown J, McEniery CM, Wilkinson IB: Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. J Am Coll Cardiol 2007;50:852–858.
31.
Orso E, Werner T, Wolf Z, Bandulik S, Kramer W, Schmitz G: Ezetimib influences the expression of raft-associated antigens in human monocytes. Cytometry A 2006;69:206–208.
32.
Seedorf U, Engel T, Lueken A, Bode G, Lorkowski S, Assmann G: Cholesterol absorption inhibitor ezetimibe blocks uptake of oxidized LDL in human macrophages. Biochem Biophys Res Commun 2004;320:1337–1341.
33.
Efrati S, Averbukh M, Dishy V, Faygenzo M, Friedensohn L, Golik A: The effect of simvastatin, ezetimibe and their combination on the lipid profile, arterial stiffness and inflammatory markers. Eur J Clin Pharmacol 2007;63:113–121.
34.
Landmesser U, Bahlmann F, Mueller M, Spiekermann S, Kirchhoff N, Schulz S, Manes C, Fischer D, de Groot K, Fliser D, Fauler G, Marz W, Drexler H: Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 2005;111:2356–2363.
35.
Fichtlscherer S, Schmidt-Lucke C, Bojunga S, Rossig L, Heeschen C, Dimmeler S, Zeiher AM: Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: clinical evidence for ‘pleiotropic’ functions of statin therapy. Eur Heart J 2006;27:1182–1190.
36.
Piorkowski M, Fischer S, Stellbaum C, Jaster M, Martus P, Morguet AJ, Schultheiss HP, Rauch U: Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets? J Am Coll Cardiol 2007;49:1035–1042.
37.
Kuvin JT, Dave DM, Sliney KA, Mooney P, Patel AR, Kimmelstiel CD, Karas RH: Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. Am J Cardiol 2006;98:743–745.
38.
Thoenes M, Oguchi A, Nagamia S, Vaccari CS, Hammoud R, Umpierrez GE, Khan BV: The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome. Int J Clin Pract 2007;61:1942–1948.
39.
Tavintharan S, Sivakumar M, Lim SC, Sum CF: Niacin affects cell adhesion molecules and plasminogen activator inhibitor-1 in HepG2 cells. Clin Chim Acta 2007;376:41–44.
40.
Westphal S, Borucki K, Taneva E, Makarova R, Luley C: Extended-release niacin raises adiponectin and leptin. Atherosclerosis 2007;193:361–365.
41.
Muhlestein JB, May HT, Jensen JR, Horne BD, Lanman RB, Lavasani F, Wolfert RL, Pearson RR, Yannicelli HD, Anderson JL: The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. J Am Coll Cardiol 2006;48:396–401.
42.
Tsimihodimos V, Kostoula A, Kakafika A, Bairaktari E, Tselepis AD, Mikhailidis DP, Elisaf M: Effect of fenofibrate on serum inflammatory markers in patients with high triglyceride values. J Cardiovasc Pharmacol Ther 2004;9:27–33.
43.
Dragomir E, Tircol M, Manduteanu I, Voinea M, Simionescu M: Aspirin and PPAR-alpha activators inhibit monocyte chemoattractant protein-1 expression induced by high glucose concentration in human endothelial cells. Vascul Pharmacol 2006;44:440–449.
44.
Zhao SP, Ye HJ, Zhou HN, Nie S, Li QZ: Gemfibrozil reduces release of tumor necrosis factor-alpha in peripheral blood mononuclear cells from healthy subjects and patients with coronary heart disease. Clin Chim Acta 2003;332:61–67.
45.
Lowe GD: Local inflammation, endothelial dysfunction and fibrinolysis in coronary heart disease. Clin Sci (Lond) 2006;110:327–328.
46.
Esposito K, Marfella R, Ciotola M, Di Palo C, Giugliano F, Giugliano G, D’Armiento M, D’Andrea F, Giugliano D: Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA 2004;292:1440–1446.
47.
Verhamme P, Quarck R, Hao H, Knaapen M, Dymarkowski S, Bernar H, Van Cleemput J, Janssens S, Vermylen J, Gabbiani G, Kockx M, Holvoet P: Dietary cholesterol withdrawal reduces vascular inflammation and induces coronary plaque stabilization in miniature pigs. Cardiovasc Res 2002;56:135–144.
48.
Robins SJ, Bloomfield HE: Fibric acid derivatives in cardiovascular disease prevention: results from the large clinical trials. Curr Opin Lipidol 2006;17:431–439.
49.
Davignon J: Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004;109:III39–III43.
50.
Robinson JG, Smith B, Maheshwari N, Schrott H: Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol 2005;46:1855–1862.
51.
Mausner-Fainberg K, Luboshits G, Mor A, Maysel-Auslender S, Rubinstein A, Keren G, George J: The effect of HMG-CoA reductase inhibitors on naturally occurring CD4(+)CD25(+) T cells. Atherosclerosis 2007, E-pub ahead of print.
52.
Prasad K: C-reactive protein (CRP)-lowering agents. Cardiovasc Drug Rev 2006;24:33–50.
53.
Knopp RH: Drug treatment of lipid disorders. N Engl J Med 1999;341:498–511.
54.
Kinlay S: Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis. J Am Coll Cardiol 2007;49:2003–2009.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.